BEAM-101 shows sustained benefits as treatment for sickle cell
BEAM-101, a one-time, gene-edited cell therapy, continues to show durable therapeutic benefits more than one year after treatment in people with sickle cell disease (SCD), according to new data from the Phase 1/2 BEACON trial. The treatment’s developer, Beam Therapeutics, shared data from the first 17 patients dosed…